Safety Analysis of Intravenous Rapid Infusion of Obinutuzumab in Patients With B-cell Non-Hodgkin's Lymphoma in China

NCT05510219 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Obinutuzumab
Rapid Infusion
Intravenous Infusion Reaction

Interventions

DRUG: intravenous rapid infusion of obinutuzumab

Sponsor

The First Affiliated Hospital with Nanjing Medical University